EGFR and head and neck cancer: In 2004, positive results from a phase 3 trial of EGFR-targeted antibody, cetuximab with concurrent radiotherapy for head and neck cancer suggested EGFR inhibitors may be radiosensitizers.73 The earliest EGFR-TKI/WBRT combination studies were occurring simultaneously.